Sorrento Therapeutics (SRNE) Competitors $0.0014 0.00 (-12.50%) As of 07/18/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRNE vs. PRFX, VRAX, JAGX, ADTX, ONCO, PTN, AWH, ALZN, CDT, and PCSAShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include PainReform (PRFX), Virax Biolabs Group (VRAX), Jaguar Animal Health (JAGX), Aditxt (ADTX), Onconetix (ONCO), Palatin Technologies (PTN), Aspira Women's Health (AWH), Alzamend Neuro (ALZN), Conduit Pharmaceuticals (CDT), and Heatwurx (PCSA). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Its Competitors PainReform Virax Biolabs Group Jaguar Animal Health Aditxt Onconetix Palatin Technologies Aspira Women's Health Alzamend Neuro Conduit Pharmaceuticals Heatwurx Sorrento Therapeutics (NASDAQ:SRNE) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Which has more risk & volatility, SRNE or PRFX? Sorrento Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, PainReform has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Do insiders & institutionals have more ownership in SRNE or PRFX? 0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is SRNE or PRFX more profitable? Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A PainReform N/A N/A N/A Do analysts prefer SRNE or PRFX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation and earnings, SRNE or PRFX? PainReform has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.01-$572.84MN/AN/APainReformN/AN/A-$14.59M-$147.33-0.01 Does the media refer more to SRNE or PRFX? In the previous week, PainReform's average media sentiment score of 0.66 beat Sorrento Therapeutics' score of 0.00 indicating that PainReform is being referred to more favorably in the news media. Company Overall Sentiment Sorrento Therapeutics Neutral PainReform Positive SummaryPainReform beats Sorrento Therapeutics on 5 of the 7 factors compared between the two stocks. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$772K$276.34M$5.55B$9.40BDividend YieldN/AN/A3.75%4.03%P/E RatioN/AN/A28.0119.82Price / Sales0.01430.80432.8198.20Price / CashN/A22.4436.1658.27Price / BookN/A9.998.125.65Net Income-$572.84M-$110.10M$3.25B$257.91M7 Day PerformanceN/A0.42%1.68%3.38%1 Month PerformanceN/A15.99%7.30%11.11%1 Year PerformanceN/A20.34%32.89%18.99% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento Therapeutics0.5127 of 5 stars$0.00-12.5%N/A-84.4%$772K$60.32M0.00800PRFXPainReform0.4334 of 5 stars$1.43+2.1%N/A-31.0%$2.82MN/A-0.014VRAXVirax Biolabs Group2.165 of 5 stars$0.86+1.2%$3.00+248.8%-16.5%$2.75M$6.33K0.005News CoveragePositive NewsJAGXJaguar Animal Health2.5872 of 5 stars$2.54-1.6%$60.00+2,262.2%-97.7%$2.63M$11.69M0.0050ADTXAditxtN/A$1.12-8.9%N/A-100.0%$2.61M$130K0.0060Gap DownHigh Trading VolumeONCOOnconetix0.2193 of 5 stars$4.31-7.3%N/A-99.5%$2.48M$2.52M0.0012News CoveragePTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeAWHAspira Women's HealthN/A$0.08-12.5%$5.50+6,607.3%-94.5%$2.44M$9.18M-0.07110High Trading VolumeALZNAlzamend Neuro2.1818 of 5 stars$2.88-2.0%$180.00+6,150.0%-90.4%$2.35MN/A0.004CDTConduit Pharmaceuticals0.3923 of 5 stars$2.42-17.1%N/A-99.5%$2.33MN/A0.003Gap DownHigh Trading VolumePCSAHeatwurx2.2249 of 5 stars$0.19-0.5%$2.00+932.0%-87.0%$2.32MN/A-0.0620 Related Companies and Tools Related Companies PainReform Competitors Virax Biolabs Group Competitors Jaguar Animal Health Competitors Aditxt Competitors Onconetix Competitors Palatin Technologies Competitors Aspira Women's Health Competitors Alzamend Neuro Competitors Conduit Pharmaceuticals Competitors Heatwurx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
